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2262guidelines for primary prevention
of sudden cardiac death in high-
risk patients with HF (3). On the
basis of the criteria for deter-
mining “high risk” by these
guidelines, however, up to 70%
of patients who receive an ICD
never have a malignant arrhythmia
(4,5), and somewhere between
15% and 40% of patients who
are eligible for an ICD never
receive one (6). Moreover, the
majority of sudden deaths occur
in patients with HF who do not
meet the current criteria for ICD
implantation (7–9). These data
suggest that current risk strati-
ﬁcation with the use of markers
such as left ventricular ejection
fraction alone is suboptimal
(10). Other methods used for
risk stratiﬁcation include signal-averaged electrocardiography (sensitivity of 62.4% and
speciﬁcity of 77.4% at 2 years) (11), T-wave alternans
(sensitivity of 74% and speciﬁcity of 44% at 1 year) (12),
and invasive electrophysiological testing (sensitivity of
62% and speciﬁcity of 62% at 1 year) (11), techniques that
are not widely used because of poor accuracy as well as
equipment and personnel costs required for implementation.
In addition, although risk may change over time, these more
demanding techniques are often limited to a single assess-
ment per patient. Therefore, there is an unmet need for a
convenient, inexpensive, and non-invasive test to stratify
risk for sudden cardiac death and arrhythmias in the HF
population.
Alternative mRNA splicing is a post-transcriptional
mechanism that can change substantially the pattern of
gene expression by creating a variety of gene products from a
single DNA message. Up to 95% of multi-exon human
genes have alternative spliced forms, which suggests that
alternative splicing is one of the most signiﬁcant compo-
nents of the functional complexity of the human genome
(13,14). We previously reported that both angiotensin II and
hypoxia, signals common to HF, increase two myocardial
splicing factors, RBM25 and associated factor LUC7L3
(15,16). The activated RMB25/LUC7L3 splicing complex
increases SCN5A C (VC) and D (VD) variants, decreases
the full-length SCN5A transcript and protein, and decreases
Naþ current (17). Interestingly, HF results in Naþ current
reductions in the range of those seen in Brugada syndrome,
an inherited arrhythmogenic condition at high risk for
sudden cardiac death (16,18). SCN5A variants result from
splicing at cryptic splice sequences in the terminal exon of
SCN5A (exon 28) (16,19). SCN5A variants are shorter and
encode prematurely truncated, nonfunctional Naþ channel
proteins missing part of the C terminus and can represent>50% of the SCN5A transcripts during HF (16,19). A
mouse model of this degree of variant expression showed an
80% reduction in cardiac Naþ current, a signiﬁcant reduc-
tion in myocardial conduction velocity, and an increase in
arrhythmic risk (19).
SCN5A transcripts and variants have been noted in
circulating white blood cells (WBCs) (16,19). Circulating
molecular biomarkers are attractive because of the conve-
nience and comfort of access compared with more tradi-
tional methods. Therefore, we sought to determine the
association of expression levels of SCN5A cardiac sodium
(Naþ) channel mRNA splice variants in WBCs with risk for
arrhythmias in HF.Methods
Correlation of cardiac tissue and circulating levels of
VC and VD variants. Simultaneous human blood and
heart tissue were obtained with an institutional review
board–approved protocol (2009–0881) at Christ Advocate
Hospital from patients undergoing left ventricular assist
device implantation. These patients were not included in the
clinical trial. The characteristics of these patients are pre-
sented in Table 1.
Clinical characteristics of the study population and
recruitment criteria. This was a cross-sectional, cohort,
comparison trial entitled “Sodium Channel Splicing in
Heart Failure Trial” (SOCS-HEFT, NCT01185587) and
conducted at the University of Illinois at Chicago and the
Jesse Brown Veterans Administration Medical Center
(JBVAMC) in Chicago, Illinois. The study was approved
by the Collaborative University of Illinois at Chicago/
Northwestern/JBVAMC Institutional Review Board. All
study subjects signed a written, informed consent before
enrollment. Subjects were adult patients (age 18 years)
with systolic HF (deﬁned by echocardiography-derived left
ventricular ejection fraction or LVEF 50%). The subjects
were assigned to four groups: those who did not have HF
(i.e., control); those with HF without an ICD (HF); those
with HF, an ICD, and no evidence of appropriate event-
driven therapy [ICD(–)Event]; and ﬁnally, those with HF,
an ICD, and evidence of appropriate event-driven therapy
[ICD(þ)Event]. Control patients were deﬁned by normal
left ventricular systolic and diastolic function by echocar-
diographic assessment. The pre-enrollment evaluation for all
groups included reviewing the electronic medical records
and subject interviews for history, a physical examination,
and current medication at the time of enrollment. De-
mographic data obtained included age, race, body mass in-
dex, and New York Heart Association (NYHA) functional
class.
ICD implantation was performed at least 1 year before
enrollment. An appropriate ICD event was adjudicated by
an independent, blinded, clinical cardiac electrophysiologist.
An “event” was deﬁned as any device therapy delivered to
interrupt ventricular ﬁbrillation or ventricular tachycardia
Table 1
Clinical Characteristics of Patients Used for Correlation of SCN5A Variants
Between Myocardial Tissue and Blood
Subject ID Age, yrs Sex Race
Ischemic
Cardiomyopathy EF WBC Count
Tissue-1 65 M Asian Y 20 NA
Tissue-2 58 M Caucasian Y 20 8.1
Tissue-3 58 F AA Y 20 NA
Tissue-4 70 M Caucasian N >20 NA
Tissue-5 47 M Caucasian N 20 NA
Tissue-6 72 M Caucasian Y 20 7.2
Tissue-7 70 F Caucasian Y >20 NA
Tissue-8 34 M AA N 20 14.4
Tissue-9 72 M Hispanic N 20 NA
Tissue-10 78 M Caucasian Y >20 8.7
Tissue-11 63 M AA N 20 10.3
Tissue-12 58 M AA N 20 10.0
Tissue-13 67 F AA Y 20 8.9
AA ¼ African American; EF ¼ ejection fraction; N ¼ no; NA ¼ not available; WBC ¼ white blood cell; Y ¼ yes.
JACC Vol. 63, No. 21, 2014 Gao et al.
June 3, 2014:2261–9 Circulating Sodium Channel Variants and Arrhythmia
2263excluding antitachycardia pacing. ICD programming was at
the discretion of the attending physician. The ICD implant
indication was predominantly primary prevention (77%). All
LVEF determinations were made by means of echocardi-
ography or cardiac magnetic resonance imaging. LVEF was
determined in a 2-year window before enrollment.
Exclusion criteria. Any patient with a history of congenital
heart disease or use of illicit drugs was excluded. Patients
receiving immunosuppressive medications or who had evi-
dence of a chronic infection, acute or chronic inﬂammatory
illness, or any illness expected to result in death within 18
months of enrollment were excluded. Control patients had
to be free of HF symptoms, diastolic dysfunction, and left
ventricular systolic dysfunction documented by any cardiac
imaging or diagnosis in the electronic medical record within
1 year of study enrollment. Other exclusion criteria for the
control group included long-QT syndrome, Brugada syn-
drome, or a history of signiﬁcant illness (i.e., myocardial
infarction, cardiac hospitalization, cardiac arrhythmia, infec-
tion, or cancer) within 12 months of study enrollment.
Laboratory methods. Blood samples were collected in
PAXgene Blood RNA tubes (Becton Dickinson, Franklin
Lakes, New Jersey), following the manufacturer’s proce-
dure. Samples were stored for up to 3 days at room tem-
perature or 5 days at 2C to 8C. Total RNA was isolated
with the use of the PAXgene Blood RNA isolation kit
and was then converted to cDNA with the use of the
High Capacity cDNA Reverse Transcription Kit (Qiagen,
Valencia, California).
Total RNA was isolated from WBCs and human heart
tissue with the use of the RNeasy Mini and RNeasy Lipid
Tissue Mini Kits, respectively (Qiagen), and then were
converted to cDNA with the use of the High Capacity
cDNA Reverse Transcription Kit (Qiagen). Only samples
with an optical density of 260/280>1.8, an optical density of
260/230 >1.5, and total RNA >6 mg were used. Both tissue
and blood samples were stored in liquid nitrogen. Underthese conditions, repeated measures of the same sample
varied by <2%. Quantitative real-time reverse-transcriptase
polymerase chain reaction (qRT-PCR) was performed to
detect the abundance of SCN5A variants by use of iQ SYBR
Green Supermix (Bio-Rad) and 7500 Fast Real-Time PCR
System (Life Technologies). The primer sequences used
were HE27F (50-CTGCGCCACTACTACTTCACCAA
CA-30); HSCN5AE28A/R (50-GGAAGAGCGTCGG
GGAGAAGAAGTA-30); HSCN5AE28C/R (50-TCT
CTTCTCCCCTCCTGCTGGTCA-30); and HSCN5
AE28D/R (50-GGAAGAGCGTCGGGGAGAAGAA
GTA-30). qRT-PCR thermal cycling conditions were an
initial uracil-N-glycosylase incubation at 50C for 2 mi-
nutes. iTaq DNA polymerase was activated with an initial
denaturation step at 95C for 5minutes, followed by cycles of
denaturation at 95C for 15 seconds and annealing and
extension at 60Cfor 1minute. Each samplewasmeasured for
the target gene SCN5A, VC, VD, and b-actin. Samples were
run in triplicate and averaged. Representative qRT-PCR
ampliﬁcation plots and the sample data are shown in Online
Figure 1 and Online Table 1. To correct for WBC SCN5A
expression between subjects, variants levels were expressed as a
percentage of the variant with respect to the total Naþ channel
mRNA including variants and normalized to the level of
b-actin.
Statistical analysis. Age, sex, race, ischemia (deﬁned as a
chart review revealing a diagnosis of coronary artery disease,
ischemic cardiomyopathy, previous coronary bypass surgery,
previous percutaneous coronary intervention, or test results
indicating obstructive coronary artery disease), LVEF, med-
ications, NYHA class, and QRS duration measurements were
recorded. Clinical characteristics were reported as mean SD
for continuous variables and frequencies for categorical vari-
ables. Differences between the groups were examined by
means of t tests and chi-square tests for continuous and
categorical variables, respectively. Results with values of p <
0.05 were considered statistically signiﬁcant in all analyses.
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2264Linear regression, on the basis of ordinary least squares,
was used to determine the degree of correlation between
normalized variant levels in the ventricle and blood. A
probability value <0.05 was taken to indicate statistical
correlation. The diagnostic odds ratio (DOR) is an overall
measure of diagnostic accuracy that combines both sensi-
tivity and speciﬁcity: [sensitivity/(1–sensitivity)]/[(1–spec-
iﬁcity)/speciﬁcity]. We compared the summary DORs and
their corresponding 95% CIs across different diagnostic
predictors: normalized variants VC and VD in the blood,
NYHA class III/IV, angiotensin-converting enzyme
(ACE) inhibitors, antiarrhythmic drugs, LVEF 20%,
and QRS duration 120 ms. Univariate analysis was
performed to calculate DORs and their corresponding
95% CIs.
Receiver operating characteristic (ROC) curves were
generated for both splicing variants and LVEF 20%.
Sensitivity (the proportion of true-positive ICD patients
with an event) and the speciﬁcity (the proportion of ICD
patients without an event) were evaluated. A commonly
used measure of overall diagnostic effectiveness is the
Youden index, which is deﬁned as (sensitivityþspeci-
ﬁcity)–1. We determined the optimal cutoff value by
maximizing the Youden index. The sensitivities and
speciﬁcities were calculated from the data across all
possible cutoff values within the range of the test results,
and we selected the cutoff value leading to the highest
Youden index.Results
Correlation of cardiac tissue and circulating levels of VC
and VD variants. Paired analysis of SCN5A variants from
circulating WBC and ventricular tissue demonstrated strong
correlation (Fig. 1) (r ¼ 0.78 and 0.75, respectively for
variants VC and VD), which demonstrates that WBC-derived
expression of SCN5A variants are correlative of levels inFigure 1 Correlation of Cardiac Tissue and WBC mRNA Abundances
(A) Tissue levels of the variant VC as a function of WBC levels measured in the same pat
same patient. The best-ﬁt linear regression is displayed as a solid black line. Gray lines ¼
variant D; WBC ¼ white blood cell.myocardial tissue. Online Figure 2 shows that the variant
levels were independent of the WBC count.
SCN5A variant expression in HF. Table 2 shows the
clinical characteristics of patients enrolled in the study. By
omnibus F test in the one-way analysis of variance, both VC
and VD varied with NYHA class, b-blocker use, and anti-
arrhythmic drug use (amiodarone in all cases except for
three patients in the ICD(þ)Event group whose records
indicated use of digoxin, sotalol, and an unspeciﬁed drug,
respectively) (Online Table 2). VC but not VD was inﬂu-
enced by QRS duration. Figure 2 displays median and
interquartile ranges (IQR) for VC and VD across the three
groups. Patients in the HF and ICD(–)Event group
exhibited signiﬁcantly lower median and IQR for both
WBC-derived VC and VD variants compared with patients
in the ICD(þ)Event group [VC: HF, 2.1 (IQR: 1.7 to 2.5);
ICD(–)Event, 2.5 (IQR: 2.1 to 3.1); ICD(þ)Event, 7.3
(IQR: 6.8 to 8.4); VD: HF, 2.8 (IQR: 2.5 to 3.1); ICD(–)
Event, 1.7 (IQR: 1.1 to 2.0); ICD(þ)Event, 6.6 (IQR:
6.3 to 7.8). The expression of VC and VD variants were also
signiﬁcantly increased in all three HF groups (HF, ICD(–)
Event, ICD(þ)Event) compared with the control group
(p < 0.05).
Effect of population characteristics on SCN5A variant
expression. There was no difference in the expression of
VC and VD across races (p ¼ NS) (Figs. 3A and 3B), be-
tween sexes (p ¼ NS) (Figs. 3C and 3D), between subjects
with an ischemia history and those without an ischemia
history (p ¼ NS) (Figs. 3E and 3F), or between subjects
with an LVEF20% and those with LVEF>20% (p¼ NS)
(Figs. 3G and 3H). Worsening NYHA class, however, was
associated with an induction of both WBC-derived SCN5A
variants (NYHA class I to II versus NYHA class III to IV:
2.8  1.7 vs. 4.1  2.7 and 2.5  1.6 vs. 3.8  2.4 for
VC and VD, respectively, p < 0.05 for each) (Figs. 3I and 3J).
VC expression also demonstrated signiﬁcant changes between
QRS duration 120 ms vs. >120 ms (3.0  2.1 vs. 4.2  2.6,of SCN5A Variants VC and VD
ient. (B) Tissue levels of the variant VD as a function of WBC levels measured in the
95% CIs. mRNA ¼ messenger ribonucleic acid; VC ¼ SCN5A variant C; VD ¼ SCN5A
Table 2 Clinical Characteristics of the Study Population
Control
(n ¼ 28)
HF
(n ¼ 43)
ICD Without Event
(n ¼ 42)
ICD With Event
(n ¼ 21)
p Value
(VC)
p Value
(VD)
Age, yrs 68.1  12.1 59.9  15.1 63.5  11.1 62.1  12.0 0.317 0.485
(age 60 yrs)
Male 26 (92.9) 28 (65.1) 29 (69.0) 15 (71.4) 0.777 0.722
Race
African American 23 (82.1) 29 (67.4) 26 (61.9) 16 (76.2) 0.705 0.575
Caucasian 5 (17.9) 3 (7.0) 5 (11.9) 1 (4.8) 0.470 0.422
Hispanic 0 (0) 9 (20.9) 9 (21.4) 4 (19.0) 0.493 0.432
Asian 0 (0) 1 (2.3) 1 (2.4) 0 (0) 0.839 0.079
Other 0 (0) 1 (2.3) 1 (2.4) 0 (0) 0.532 0.646
NYHA class 0.006 0.002
(I/II vs. III/IV)
I 0 (0) 2 (4.7) 0 (0) 0 (0)
II 0 (0) 9 (20.9) 9 (21.4) 0 (0)
III 0 (0) 11 (25.6) 18 (42.9) 4 (19.0)
IV 0 (0) 21 (48.8) 15 (35.7) 17 (81.0)
Ischemic cardiomyopathy 7 (25.0) 19 (44.2) 31 (73.8) 12 (57.1) 0.814 0.462
Medications
Beta-blocker 8 (28.6) 35 (81.4) 37 (88.1) 21 (100) 0.005 0.046
ACE inhibitor 12 (42.9) 29 (67.4) 29 (69.0) 15 (71.4) 0.661 0.607
ARB 3 (10.7) 3 (7.0) 7 (16.7) 4 (19.0) 0.450 0.709
Aldosterone antagonist 0 (0) 3 (7.0) 14 (33.3) 8 (38.1) 0.301 0.904
Antiarrhythmic drug 0 (0) 2 (4.7) 4 (9.5) 8 (38.1) 0.021 0.052
QRS duration >120 ms 2 (7.1) 8 (20.0) 18 (43.9) 15 (71.4) 0.014 0.150
LVEF, % 54.6  1.9 26.0  7.7 27.4  7.0 26.1  5.5 0.414 0.382
(LVEF 20%)
Values are mean  SD or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; HF¼ heart failure; ICD ¼ implantable cardioverter-deﬁbrillator; LVEF¼ left ventricular ejection fraction; NYHA ¼ New York Heart
Association.
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niﬁcance was evident in VD expression (2.9  1.9 vs. 3.6 
2.4, p > 0.05) (Fig. 3L).
Predictors of ICD events. By univariate analysis (Fig. 4),
NYHA class III/IV (DOR, 7.65; 95% CI: 2.17 to 27.00),Figure 2 WBC Expression of SCN5A Variants in the Test Groups
(A) Fold induction compared with control of SCN5A variant VC in the heart failure (HF), im
induction compared with control of SCN5A variant VD in the HF, ICD(–)Event, and ICD(þ)
minimum, and maximum. *p < 0.05 as compared with control. **p < 0.05 comparing t
independent-samples Mann-Whitney U test. Abbreviations as in Figure 1.antiarrhythmic drug use (DOR, 5.85; 95% CI: 1.51 to
22.70), WBC-derived VC expression (DOR, 3.85; 95% CI:
2.00 to 7.43), WBC-derived VD expression (DOR, 3.04;
95% CI: 1.83 to 5.05), and QRS duration 120 ms (DOR,
3.19; 95% CI: 1.03 to 9.89) demonstrated association withplantable cardioverter-deﬁbrillator (ICD)(–)Event, and ICD(þ)Event groups. (B) Fold
Event groups. Fold induction values are displayed as median, interquartile ranges,
he ICD(þ)Event group with the combined HF and ICD(–)Event groups by means of
Figure 3 Effect of Clinical Characteristics on WBC Expression of SCN5A VC and VD
A, C, E, G, I, and K as well as B, D, F, H, J, and L compare the effects of race, sex, origin of the cardiomyopathy, left ventricular ejection fraction (LVEF), New York Heart
Association (NYHA) heart failure stage, and QRS duration on WBC variant VC and VD levels, respectively. Abbreviations as in Figures 1 and 2.
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(DOR, 2.11; 95% CI: 0.22 to 20.12) and ACE inhibitors
(DOR, 1.12; 95% CI: 0.36 to 3.54) were not associated with
ICD events.
Sensitivity and speciﬁcity of SCN5A variants for deter-
mination of ICD events. ROC curves were generated
to evaluate the performance of the expression of theWBC-derived variants in distinguishing between the ICD
patients with and without the events and then were
compared with those generated for an LVEF 20%. The
area under the ROC curve was 0.98 (95% CI: 0.95 to 1.00),
0.97 (95% CI: 0.93 to 1.00), and 0.56 (95% CI: 0.41 to
0.71) for VC, VD, and LVEF 20%, respectively (Fig. 5).
The values for the optimal Youden index and cutoff as well
Figure 4 Univariate Analysis of Clinical Characteristics on Discrimination of ICD Events
Data are presented as odds ratios and 95% conﬁdence intervals (CIs). ACE ¼ angiotensin-converting enzyme; ICD ¼ implantable cardioverter-deﬁbrillator; other abbreviations as
in Figure 3.
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are shown in Table 3. To address any model overﬁtting, we
performed a 7-fold cross-validation of each logistic regres-
sion associated with ICD intervention (from VC, VD, and
LVEF <20%) and plotted the distribution of sensitivity and
speciﬁcity values for cutoffs on the basis of the regressions on
the ROC curves. The plots (Online Fig. 3) illustrate that
both VC and VD variants provided performance superior to
LVEF in our data set.Figure 5
Receiver Operating Characteristic Curves for
WBC SCN5A Variant VC and VD Discrimination of
ICD Events
Receiver operating characteristic (ROC) curves for normalized VC and VD are
compared with LVEF 20%. Areas under the ROC curves (95% CI) are 0.98
(0.95 to 1.00), 0.97 (0.93 to 1.00), and 0.56 (0.41 to 0.71) for VC, VD, and
LVEF 20%, respectively. Line of no discrimination is also shown. Abbreviations
as in Figures 1 to 3.Discussion
Alterations in sodium current, the main current for cardiac
conduction, are associated with arrhythmogenesis (20).
Since the cloning of SCN5A, encoding the a-subunit of
the Naþ channel (21), hundreds of mutations have been
reported to cause inherited sudden death syndromes such as
Brugada syndrome, the third variant of long-QT syndrome,
and sudden infant death (20,22). Moreover, we have shown
previously that abnormal mRNA splicing results in SCN5A
variants that can contribute to arrhythmic risk and that these
variants are increased in HF (16,17,19).
With the use of left ventricular assist device core samples
and blood samples from the same patient, we now show a
signiﬁcant correlation between normalized variant expres-
sion levels in the heart and blood. The results also indicate a
graded association between levels of circulating SCN5A
variants and an increasing risk of ICD events in patients
from control to HF to HF with ICD events. Patients with
HF who had received appropriate ICD intervention had
signiﬁcantly higher levels of SCN5A splice variants
compared with control patients and patients who had not
received an intervention. As expected, patients with HF with
an ICD and those without an ICD but with no intervention
had similar variant levels. Moreover, the separation betweenTable 3 Optimal Discrimination Values for VC and VD Variants
Index Test
Optimal
Cutoff
Value
Optimal
Youden
Index
Corresponding
Sensitivity
(95% CI)
Corresponding
Speciﬁcity
(95% CI)
Normalized VC 4.2 0.9 1.0 (0.85–1.00) 0.9 (0.78–0.96)
Normalized VD 2.9 0.9 1.0 (0.85–1.00) 0.9 (0.78–0.96)
LVEF 20% 4.5 0.1 0.6 (0.41–0.79) 0.5 (0.35–0.64)
CI ¼ conﬁdence intervals; LVEF ¼ left ventricular ejection fraction; VC ¼ SCN5A variant C;
VD ¼ SCN5A variant D.
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stratify patients with HF.
The discriminatory capacity of the variant expression to
identify groups with and groups without ICD events was
independent of sex, race, etiology of myopathy, or severity
of LVEF. SCN5A variant expression was increased with
higher NYHA class, consistent with the notion that these
patients have worsening HF symptoms and are at higher
risk from HF complications such as arrhythmias. Because
longer QRS duration is a manifestation of cardiac con-
duction disease and is associated with reduced functional
sodium channels (23–26), observations of higher variant
levels in patients with longer QRS duration were also
consistent. Interestingly, variant levels were not associated
with severity of LVEF. Because LVEF severity beyond the
initial threshold of 30% or 35% has not been a reliable in-
dicator for further risk stratiﬁcation for ICD implantation
(27–29), the current data indicate that measures of circu-
lating variant expression levels may give added information
to risk reﬂected by left ventricular function. Because of the
cardiac-speciﬁc nature of the pathophysiological role of
SCN5A variants and the high degree of correlation between
WBC-derived SCN5A variant levels and ICD in-
terventions, we speculate that circulating SCN5A variants
may supplement current methods to improve discrimina-
tion of patients who will most probably beneﬁt from ICD
implantation.
Study limitations. There are a number of limitations to
this study. The small sample size may limit the applicability
of the ﬁndings to larger population-level cohorts. For
example, sample size may have masked weak associations of
variants with other potential covariates or identiﬁcation of
other predictors of arrhythmic risk. Because of the retro-
spective imaging and ICD data, unforeseen biases may have
been introduced that might reduce the power of WBC-
derived variants. Analysis of patients with ICD device in-
terventions for nonlethal arrhythmias, however, revealed that
device intervention alone did not alter SCN5A variants
levels (data not shown). Additionally, ICD programming
was not controlled in this study design. Therefore, potential
nonsustained events may have been counted, altering the
calculated power of the variant levels. Exclusion of anti-
tachycardia pacing as an event mitigates some of this
concern. Although this study suggested that the association
of SCN5A mRNA splice variants was independent of race,
the total number of patients and limited numbers of
Caucasian, Hispanic, or Asian patients make it difﬁcult to
be certain that the ﬁndings apply similarly to all racial
groups. We did not evaluate the correlation of variants with
multiple ICD interventions in the ICD(þ)Event group or
over longer than the deﬁned 1-year period. Despite the
correlation between elevated levels of VC and VD with
ICD events, it is possible that not all arrhythmic conditions
will be similarly associated. Finally, the cost/beneﬁt ratio of
any combination of predictive parameters remains to be
determined.Conclusions
We have shown that levels of circulating WBC-derived
SCN5A mRNA variants are representative of levels in the
myocardium. Moreover, the SCN5A variant levels increased
with risk for sudden cardiac death, and variant levels were
signiﬁcantly elevated in patients who received an ICD
intervention. The degree of separation of variant levels be-
tween patients with HF with and those without an ICD
intervention suggests that variant levels had a strong power
to discriminate between these two groups. If true in pro-
spective validation trials, WBC SCN5A variant level de-
terminations may help identify which patients with HF
might beneﬁt most from device implantation.
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